Jamie Castillo
Internal Medicine · Houston, MSNPI 1538179536
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 662 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 38.2% of the total. Among internal medicine clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 662 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Amgen$2K
- Mallinckrodt Hospital Products Inc.$1K
- Novartis$839
- UCB, Inc.$733
- Pfizer$680
- plus $2K from 13 others
What the payments were for
- Food & beverage$12,268100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 209 | $4,687 |
| Amgen | 147 | $2,464 |
| Mallinckrodt Hospital Products Inc. | 66 | $1,225 |
| Novartis | 60 | $839 |
| UCB, Inc. | 50 | $733 |
| Pfizer | 45 | $680 |
| Aurinia Pharma U.S., Inc. | 19 | $422 |
| ANI Pharmaceuticals, Inc. | 16 | $266 |
| Johnson & Johnson | 9 | $188 |
| Sanofi | 9 | $158 |
| GSK | 7 | $153 |
| Lilly USA, LLC | 6 | $96 |
| Bristol Myers Squibb | 6 | $94 |
| Otsuka America Pharmaceutical, Inc. | 3 | $84 |
| AstraZeneca | 4 | $68 |
| Novo Nordisk | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| Boehringer Ingelheim | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
How this compares
$12,275 in reported general payments places this provider in the 95th percentile of 846 internal medicine providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 86 | $635,946 |
| Humira(Cf) PenAdalimumab | 38 | $347,393 |
| Humira(Cf)Adalimumab | 27 | $213,791 |
| EnbrelEtanercept | 23 | $184,125 |
| Xeljanz XrTofacitinib Citrate | 31 | $182,454 |
| RinvoqUpadacitinib | 28 | $172,908 |
| OzempicSemaglutide | 141 | $151,972 |
| MounjaroTirzepatide | 127 | $145,142 |
| LinzessLinaclotide | 81 | $74,783 |
| EliquisApixaban | 81 | $74,571 |
| TrulicityDulaglutide | 41 | $43,829 |
| JanuviaSitagliptin Phosphate | 37 | $34,064 |
| JardianceEmpagliflozin | 37 | $33,383 |
| FarxigaDapagliflozin Propanediol | 34 | $27,707 |
| XareltoRivaroxaban | 20 | $23,819 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf), Rinvoq, Linzess | $4,687 | $461,482136 claims |
| AmgenEnbrel, Prolia | $2,464 | $205,96336 claims |
| Lilly USA, LLCMounjaro, Trulicity | $96 | $188,972168 claims |
| Novo NordiskOzempic | $42 | $151,972141 claims |
| PfizerEliquis | $680 | $74,57181 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat | $20 | $59,30768 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $68 | $37,70946 claims |
| Johnson & JohnsonXarelto | $188 | $23,81920 claims |
| GSKTrelegy Ellipta | $153 | $22,30423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Houston
- Kelly WilkinsonJackson$79K
- Shanna PettieJackson$53K
- Gabriel HernandezJackson$41K
- Indira VeerisettyRidgeland$25K
- James BridgesMadison$23K
- Brendan RossJackson$19K
- Hassan CheemaJackson$16K
- Jeffrey DennisOxford$15K
- Charles HillOxford$15K
- Paul VolanskyCorinth$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.